DexCom Other Liab vs Short Term Investments Analysis
DXCM Stock | USD 78.10 0.16 0.21% |
DexCom financial indicator trend analysis is much more than just examining DexCom Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DexCom Inc is a good investment. Please check the relationship between DexCom Other Liab and its Short Term Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Other Liab vs Short Term Investments
Other Liab vs Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DexCom Inc Other Liab account and Short Term Investments. At this time, the significance of the direction appears to have almost identical trend.
The correlation between DexCom's Other Liab and Short Term Investments is 0.94. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of DexCom Inc, assuming nothing else is changed. The correlation between historical values of DexCom's Other Liab and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of DexCom Inc are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Other Liab i.e., DexCom's Other Liab and Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.94 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Other Liab
Short Term Investments
Short Term Investments is an item under the current assets section of DexCom balance sheet. It contains any investments DexCom Inc undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that DexCom Inc can easily liquidate in the marketplace.Most indicators from DexCom's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DexCom Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. At this time, DexCom's Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Tax Provision is likely to grow to about 177.3 M, while Issuance Of Capital Stock is likely to drop about 19.7 M.
DexCom fundamental ratios Correlations
Click cells to compare fundamentals
DexCom Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Not Found
DexCom fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.4B | 4.3B | 4.9B | 5.4B | 6.3B | 6.6B | |
Total Stockholder Equity | 882.6M | 1.8B | 2.3B | 2.1B | 2.1B | 2.2B | |
Net Debt | 699.5M | 1.0B | 769.2M | 1.4B | 2.0B | 2.1B | |
Cash | 446.2M | 817.6M | 1.1B | 642.3M | 566.3M | 594.6M | |
Cash And Short Term Investments | 1.5B | 2.7B | 2.7B | 2.5B | 2.7B | 2.9B | |
Common Stock Shares Outstanding | 369.2M | 390M | 428.8M | 427.5M | 425.5M | 246.4M | |
Liabilities And Stockholders Equity | 2.4B | 4.3B | 4.9B | 5.4B | 6.3B | 6.6B | |
Total Current Assets | 2.0B | 3.4B | 3.7B | 3.7B | 4.4B | 4.6B | |
Other Current Liab | 88.5M | 400.3M | 447.6M | 753.4M | 1.2B | 1.2B | |
Total Current Liabilities | 360.2M | 614.1M | 720.8M | 1.8B | 1.6B | 1.6B | |
Property Plant And Equipment Net | 392.8M | 608.6M | 889.9M | 1.1B | 1.2B | 1.2B | |
Retained Earnings | (695.7M) | (202.1M) | (47.4M) | 479.9M | 1.0B | 1.1B | |
Accounts Payable | 256.4M | 163.3M | 189.4M | 237.9M | 276.4M | 290.2M | |
Non Current Assets Total | 425.6M | 865.7M | 1.2B | 1.7B | 1.8B | 1.9B | |
Non Currrent Assets Other | 14.2M | 21.4M | (4.5M) | 28.1M | 36.5M | 38.3M | |
Other Assets | 14.2M | 237.8M | 220.8M | 369.3M | 424.7M | 445.9M | |
Non Current Liabilities Total | 1.2B | 1.8B | 1.9B | 1.4B | 2.6B | 2.8B | |
Other Current Assets | 30M | 107.8M | 79.3M | 153.7M | 154.7M | 162.4M | |
Other Stockholder Equity | 1.6B | 2.0B | 1.9B | 1.7B | 1.1B | 1.1B | |
Total Liab | 1.5B | 2.5B | 2.6B | 3.3B | 4.2B | 4.4B | |
Property Plant And Equipment Gross | 392.8M | 608.6M | 801.8M | 1.1B | 1.7B | 1.8B | |
Accumulated Other Comprehensive Income | 2.3M | 3.2M | 500K | (11.6M) | (16.7M) | (15.9M) | |
Property Plant Equipment | 321.3M | 515.3M | 889.9M | 1.1B | 1.3B | 1.4B | |
Other Liab | 5.7M | 80.9M | 90M | 68.7M | 79.0M | 83.0M | |
Short Term Investments | 1.1B | 1.9B | 1.7B | 1.8B | 2.2B | 2.3B | |
Short Long Term Debt Total | 1.1B | 1.8B | 1.8B | 2.1B | 2.6B | 2.7B | |
Long Term Debt | 1.1B | 1.7B | 1.7B | 1.2B | 2.4B | 2.6B | |
Net Receivables | 286.3M | 428.5M | 516.6M | 752.2M | 987.5M | 1.0B | |
Inventory | 119.8M | 234.7M | 357.3M | 306.7M | 559.6M | 587.6M | |
Short Term Debt | 13.6M | 33M | 41M | 793.1M | 21.1M | 20.0M | |
Current Deferred Revenue | 1.7M | 2.2M | 2.1M | 10.1M | 18.4M | 19.3M | |
Net Tangible Assets | 864M | 1.8B | 2.2B | 2.1B | 2.5B | 2.6B | |
Good Will | 18.6M | 19.3M | 26.5M | 25.7M | 25.2M | 14.4M | |
Retained Earnings Total Equity | (695.7M) | (202.1M) | (47.4M) | 479.9M | 551.9M | 579.5M | |
Capital Surpluse | 1.7B | 2.1B | 2.5B | 2.3B | 2.6B | 1.5B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.66 | Revenue Per Share 10.089 | Quarterly Revenue Growth 0.02 | Return On Assets 0.0606 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.